Loading institutional data...
Loading institutional data...
Held by 1,336 of 5,944 reporting institutions (99th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $789.45 today, the market must believe free cash flow compounds 8.4%/yr for a decade (off $3.9B normalized FCF).
The market's 8.4% is more conservative than its 9-yr track record.
2-stage DCF · 0.10B shares · net debt -$1.1B
mean 31.0% · volatility σ 79% · implied rate exceeded in 4/9 yrs
Central path = implied 8.4%/yr growth; shaded band = ±1σ (79%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.34B 100.0% | $14.20B 100.0% | $13.12B 100.0% | $12.17B 100.0% | $16.07B 100.0% | $8.50B 100.0% | $6.56B 100.0% | $5.15B 100.0% | $5.87B 100.0% | $4.86B 100.0% |
| Cost of Revenue | — | — | — | — | — | — | $402.8M 6.1% | $237.5M 4.6% | $202.5M 3.4% | $194.6M 4.0% |
| Cost of Products | — | — | — | — | — | — | — | — | $202.5M 3.4% | $194.6M 4.0% |
| Research & Development | $5.85B 40.8% | $5.13B 36.1% | $4.44B 33.8% | $3.59B 29.5% | $2.86B 17.8% | $2.65B 31.2% | $2.45B 37.4% | $1.47B 28.5% | $2.08B 35.3% | $2.05B 42.2% |
| Selling, General & Admin | $2.70B 18.8% | $2.95B 20.8% | $2.63B 20.1% | $2.12B 17.4% | $1.82B 11.4% | $1.35B 15.8% | $1.34B 20.5% | $1.13B 21.9% | $1.32B 22.5% | $1.18B 24.2% |
| Total Operating Expenses | $10.77B 75.1% | $10.21B 71.9% | $9.07B 69.1% | $7.43B 61.1% | $7.12B 44.3% | $4.92B 57.9% | $4.35B 66.3% | $2.61B 50.7% | $3.79B 64.6% | $3.53B 72.6% |
| Operating Income | $3.58B 24.9% | $3.99B 28.1% | $4.05B 30.9% | $4.74B 38.9% | $8.95B 55.7% | $3.58B 42.1% | $2.21B 33.7% | $2.53B 49.3% | $2.08B 35.4% | $1.33B 27.4% |
| Interest Expense | $43.8M 0.3% | $55.2M 0.4% | $73.0M 0.6% | $59.4M 0.5% | $57.3M 0.4% | $56.9M 0.7% | $30.2M 0.5% | $28.2M 0.5% | $25.1M 0.4% | $7.2M 0.1% |
| Other Income (Expense), net | $1.65B 11.5% | $789.2M 5.6% | $152.2M 1.2% | $119.9M 1.0% | $379.0M 2.4% | $233.8M 2.8% | $219.3M 3.3% | $19.1M 0.4% | -$1.1M -0.0% | -$900K -0.0% |
| Pretax Income | $5.23B 36.5% | $4.78B 33.7% | $4.20B 32.0% | $4.86B 39.9% | $9.33B 58.0% | $3.81B 44.8% | $2.43B 37.0% | $2.55B 49.6% | $2.08B 35.4% | $1.33B 27.4% |
| Income Tax Expense | $725.8M 5.1% | $367.3M 2.6% | $245.7M 1.9% | $520.4M 4.3% | $1.25B 7.8% | $297.2M 3.5% | $313.3M 4.8% | $109.1M 2.1% | $880.0M 15.0% | $434.3M 8.9% |
| Net Income | $4.50B 31.4% | $4.41B 31.1% | $3.95B 30.1% | $4.34B 35.6% | $8.08B 50.2% | $3.51B 41.3% | $2.12B 32.3% | $2.44B 47.5% | $1.20B 20.4% | $895.5M 18.4% |
| Per Share | ||||||||||
| EPS (Basic) | $43.07 | $40.90 | $37.05 | $40.51 | $76.40 | $32.65 | $19.38 | $22.65 | $11.27 | $8.55 |
| EPS (Diluted) | $41.48 | $38.34 | $34.77 | $38.22 | $71.97 | $30.52 | $18.46 | $21.29 | $10.34 | $7.70 |
| Weighted Avg Shares (Basic) | 104.6M | 107.9M | 106.7M | 107.1M | 105.7M | 107.6M | 109.2M | 107.9M | 106.3M | 104.7M |
| Weighted Avg Shares (Diluted) | 108.6M | 115.1M | 113.7M | 113.5M | 112.2M | 115.1M | 114.6M | 114.8M | 115.9M | 116.3M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
5/8 of the 9 checks — 1 couldn't be scored (see above), so the score is out of the 8 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Needs granular two-year detail (receivables, PP&E, D&A, SG&A) — not fully reported.
Cash conversion lags reported earnings — watch accruals. Lower/negative accruals = higher quality (Sloan).
Comfortably covers interest; leverage rising year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
The dividend is comfortably covered — only 9% of free cash flow, leaving room to grow it and fund buybacks. Last year: $370M dividends + $3.4B buybacks = $3.8B returned on $4.1B FCF.
1 consecutive years of dividend increases.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A cash-return story — far more went to shareholders than back into the business (mature, low-reinvestment).
Reinvestment has been productive — operating income grew well per dollar put in. Current ROIC on all capital: 14%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest is easily covered by operating profit. Effective rate ~2.2% on $2.0B of debt.
Cash vs short-term debt unavailable.
Mostly long-term debt (balance-sheet current vs non-current split). A year-by-year maturity schedule wasn't disclosed for this issuer.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
EOD close · as of 2026-09-17
No material risks flagged.
Where each multiple sits in its own 14-yr range · 34th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Returns are margin-driven, not leverage-driven — higher quality.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 4.6 | 6.1 | — | — | — | — | — | — |
| R&D | 28.5 | 37.4 | 31.2 | 17.8 | 29.5 | 33.8 | 36.1 | 40.8 |
| SG&A | 21.9 | 20.5 | 15.8 | 11.4 | 17.4 | 20.1 | 20.8 | 18.8 |
| Operating Income | 49.3 | 33.7 | 42.1 | 55.7 | 38.9 | 30.9 | 28.1 | 24.9 |
| Income Tax | 2.1 | 4.8 | 3.5 | 7.8 | 4.3 | 1.9 | 2.6 | 5.1 |
| Net Income | 47.5 | 32.3 | 41.3 | 50.2 | 35.6 | 30.1 | 31.1 | 31.4 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on REGN: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
Peers = companies sharing REGN's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.